Fibrocell Science Inc (NASDAQ:FCSC) reached a new 52-week low on Friday . The stock traded as low as $1.36 and last traded at $1.47, with a volume of 180300 shares traded. The stock had previously closed at $1.52.
Several equities research analysts recently weighed in on FCSC shares. HC Wainwright reiterated a “buy” rating and set a $5.70 price objective on shares of Fibrocell Science in a research note on Friday, September 15th. Zacks Investment Research upgraded shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. ValuEngine lowered shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. Finally, Canaccord Genuity restated a “buy” rating and issued a $7.00 price target (up previously from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Fibrocell Science currently has a consensus rating of “Hold” and a consensus target price of $5.21.
Several large investors have recently made changes to their positions in the business. Pura Vida Investments LLC acquired a new stake in shares of Fibrocell Science in the third quarter valued at approximately $909,000. Parametric Portfolio Associates LLC increased its stake in shares of Fibrocell Science by 264.0% in the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock valued at $194,000 after purchasing an additional 35,000 shares during the period. Finally, Creative Planning increased its stake in shares of Fibrocell Science by 395.3% in the second quarter. Creative Planning now owns 61,090 shares of the company’s stock valued at $245,000 after purchasing an additional 48,755 shares during the period. Institutional investors own 55.81% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/12/03/fibrocell-science-fcsc-sets-new-52-week-low-at-1-36.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.